Cargando…

Approaching patients with irritable bowel syndrome

Treatment of functional gastrointestinal disorders remains difficult with many very different approaches showing similar response rates, regardless of whether they target luminal contents (e.g., presumed bacterial overgrowth), signaling within the gut wall (e.g., serotonin agonists or antagonists) o...

Descripción completa

Detalles Bibliográficos
Autor principal: Bielefeldt, Klaus
Formato: Texto
Lenguaje:English
Publicado: Medicine Reports Ltd 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950050/
https://www.ncbi.nlm.nih.gov/pubmed/20948834
http://dx.doi.org/10.3410/M2-50
_version_ 1782187619740811264
author Bielefeldt, Klaus
author_facet Bielefeldt, Klaus
author_sort Bielefeldt, Klaus
collection PubMed
description Treatment of functional gastrointestinal disorders remains difficult with many very different approaches showing similar response rates, regardless of whether they target luminal contents (e.g., presumed bacterial overgrowth), signaling within the gut wall (e.g., serotonin agonists or antagonists) or processing in the brain (e.g., cognitive behavioral therapy). Discrepancies between recent clinical trials and a meta-analysis have forced us to re-examine the use of antidepressants. Other studies have looked beyond the traditional drug therapies and have suggested other options such as dietary interventions and communication strategies that address relevant disease mechanisms and enable us to understand patient concerns, with the ultimate goal being to individualize and thus improve treatment outcomes.
format Text
id pubmed-2950050
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Medicine Reports Ltd
record_format MEDLINE/PubMed
spelling pubmed-29500502010-10-14 Approaching patients with irritable bowel syndrome Bielefeldt, Klaus F1000 Med Rep Review Article Treatment of functional gastrointestinal disorders remains difficult with many very different approaches showing similar response rates, regardless of whether they target luminal contents (e.g., presumed bacterial overgrowth), signaling within the gut wall (e.g., serotonin agonists or antagonists) or processing in the brain (e.g., cognitive behavioral therapy). Discrepancies between recent clinical trials and a meta-analysis have forced us to re-examine the use of antidepressants. Other studies have looked beyond the traditional drug therapies and have suggested other options such as dietary interventions and communication strategies that address relevant disease mechanisms and enable us to understand patient concerns, with the ultimate goal being to individualize and thus improve treatment outcomes. Medicine Reports Ltd 2010-07-14 /pmc/articles/PMC2950050/ /pubmed/20948834 http://dx.doi.org/10.3410/M2-50 Text en © 2010 Medicine Reports Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes
spellingShingle Review Article
Bielefeldt, Klaus
Approaching patients with irritable bowel syndrome
title Approaching patients with irritable bowel syndrome
title_full Approaching patients with irritable bowel syndrome
title_fullStr Approaching patients with irritable bowel syndrome
title_full_unstemmed Approaching patients with irritable bowel syndrome
title_short Approaching patients with irritable bowel syndrome
title_sort approaching patients with irritable bowel syndrome
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2950050/
https://www.ncbi.nlm.nih.gov/pubmed/20948834
http://dx.doi.org/10.3410/M2-50
work_keys_str_mv AT bielefeldtklaus approachingpatientswithirritablebowelsyndrome